Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome.

Lacy BE, Patel NK.

J Clin Med. 2017 Oct 26;6(11). pii: E99. doi: 10.3390/jcm6110099. Review.

2.

A SEARCH FOR UNHAPPY ABDOMEN: PREVALENCE OF IRRITABLE BOWEL SYNDROME IN GENERAL POPULATION.

Anand AC, Saiprasad GS, Bhalwar R.

Med J Armed Forces India. 1998 Apr;54(2):123-127. doi: 10.1016/S0377-1237(17)30500-2. Epub 2017 Jun 26.

3.

Irritable bowel syndrome.

Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC.

Nat Rev Dis Primers. 2016 Mar 24;2:16014. doi: 10.1038/nrdp.2016.14. Review.

4.

Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past.

Sood R, Ford AC.

Clin Transl Gastroenterol. 2015 Oct 8;6:e116. doi: 10.1038/ctg.2015.41. No abstract available.

5.

Evolution of the Diagnosis of Functional Gut Disorders: Is an Objective Positive Diagnostic Approach Within Reach?

Talley NJ.

Clin Transl Gastroenterol. 2015 Jul 23;6:e104. doi: 10.1038/ctg.2015.29. No abstract available.

6.

Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, Leffler DA, Marsh Z, Weitsman S, Chua KS, Barlow GM, Bortey E, Forbes W, Yu A, Chang C.

PLoS One. 2015 May 13;10(5):e0126438. doi: 10.1371/journal.pone.0126438. eCollection 2015.

7.

Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE, Burton D, Lamsam J, Lueke A, Donato LJ, Zinsmeister AR.

Neurogastroenterol Motil. 2014 Dec;26(12):1677-85. doi: 10.1111/nmo.12421. Epub 2014 Sep 22.

8.

Duodenal chromogranin a cell density as a biomarker for the diagnosis of irritable bowel syndrome.

El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T.

Gastroenterol Res Pract. 2014;2014:462856. doi: 10.1155/2014/462856. Epub 2014 Jun 16.

9.

Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.

Saha L.

World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. Review.

10.

Irritable bowel syndrome: how useful is the term and the 'diagnosis'?

Camilleri M.

Therap Adv Gastroenterol. 2012 Nov;5(6):381-6. doi: 10.1177/1756283X12442223. No abstract available.

11.

Antibiotics for the treatment of irritable bowel syndrome.

Basseri RJ, Weitsman S, Barlow GM, Pimentel M.

Gastroenterol Hepatol (N Y). 2011 Jul;7(7):455-93.

12.

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome.

Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J.

Int J Colorectal Dis. 2012 Apr;27(4):467-74. doi: 10.1007/s00384-011-1363-9. Epub 2011 Dec 2.

13.

Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome.

Dorofeyev AE, Kiriyan EA, Vasilenko IV, Rassokhina OA, Elin AF.

Clin Exp Gastroenterol. 2011;4:141-53. doi: 10.2147/CEG.S18381. Epub 2011 Jun 16.

14.

Irritable bowel syndrome: diagnostic approaches in clinical practice.

Burbige EJ.

Clin Exp Gastroenterol. 2010;3:127-37. doi: 10.2147/CEG.S12596. Epub 2010 Sep 17.

15.

Factors associated with irritable bowel syndrome symptoms in hemodialysis patients.

Fiderkiewicz B, Rydzewska-Rosołowska A, Myśliwiec M, Birecka M, Kaczanowska B, Rydzewska G, Rydzewski A.

World J Gastroenterol. 2011 Apr 21;17(15):1976-81. doi: 10.3748/wjg.v17.i15.1976.

16.

Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.

Spiegel BM, Bolus R, Harris LA, Lucak S, Chey WD, Sayuk G, Esrailian E, Lembo A, Karsan H, Tillisch K, Talley J, Chang L.

Aliment Pharmacol Ther. 2010 Nov;32(9):1192-202. doi: 10.1111/j.1365-2036.2010.04443.x. Epub 2010 Aug 30.

17.

Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review.

Whitehead WE, Drossman DA.

Am J Gastroenterol. 2010 Apr;105(4):814-20; quiz 813, 821. doi: 10.1038/ajg.2010.56. Epub 2010 Feb 23. Review.

18.

Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.

Spiegel B, Bolus R, Harris LA, Lucak S, Naliboff B, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Talley J, Mayer E, Chang L.

Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1159-70. doi: 10.1111/j.1365-2036.2009.04144.x. Epub 2009 Sep 12.

19.

The role of fecal calprotectin in investigating inflammatory bowel diseases.

Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M.

Clinics (Sao Paulo). 2009 May;64(5):421-5.

20.

Chronic diarrhoea.

Spiller R.

Gut. 2007 Dec;56(12):1756-7. No abstract available.

Supplemental Content

Support Center